导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 3.14% | 1618/4773 |
| 近一周 | -2.11% | 2395/5458 |
| 近一月 | -4.54% | 2915/5421 |
| 近一季 | -5.89% | 3004/5205 |
| 近半年 | -5.48% | 2995/4920 |
| 近一年 | 8.83% | 1244/4361 |
| 近两年 | 68.93% | 1009/2954 |
| 近三年 | 37.03% | 814/2253 |
| 成立以来 | 64.03% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
2.63% 877/4961 |
16.77% 1526/5312 |
- - |
- - |
| 2025 | 30.27% 1339/4813 |
1.86% 1531/3635 |
1.99% 1958/4076 |
22.85% 1605/4524 |
2.07% 1089/4813 |
| 2024 | 6.86% 1716/3463 |
-2.20% 1330/2808 |
-4.82% 1565/3014 |
15.26% 1771/3129 |
-0.40% 1406/3463 |
| 2023 | -5.84% 786/2656 |
7.06% 607/2280 |
-3.93% 975/2385 |
-4.33% 1115/2515 |
-4.31% 954/2655 |
| 2022 | -16.87% 525/2207 |
-12.16% 578/1919 |
2.32% 1316/2016 |
-9.70% 299/2113 |
2.43% 941/2208 |
| 2021 | 16.21% 275/1822 |
-1.19% 448/1255 |
8.98% 593/1330 |
4.24% 372/1466 |
3.52% 423/1822 |
| 2020 | 18.72% 738/1250 |
-4.94% 391/1028 |
14.71% 537/1067 |
6.39% 845/1164 |
2.34% 995/1184 |
| 2019 | - - |
- - |
- - |
- - |
- - |
| 2018 | - - |
- - |
- - |
- - |
- - |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 天弘恒生沪深港创新药精选50ETF | 0.8428 | 28.18% |
| 港股通药 | 0.8930 | 27.53% |
| 天弘恒生沪深港创新药精选50ETF发起联接A | 1.2971 | 26.78% |
| 华富中证港股通创新药指数型发起式C | 1.1445 | 26.30% |
| 万家中证港股通创新药ETF | 1.5973 | 26.27% |
| 景顺长城中证港股通创新药ETF | 1.6587 | 26.20% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2831 | 25.87% |
| 港医疗 | 0.8885 | 25.59% |
| 景顺长城中证港股通创新药ETF联接A | 1.4594 | 25.50% |
| 华富中证港股通创新药指数型发起式A | 1.1526 | 25.42% |
| 国联中证500ETF联接A VS. 长安沪深300非周期A(740101) |